Paysign Reports 43% Revenue Growth Driven by Pharmaceutical Patient Affordability Segment

Paysign (PAYS) reported a significant third-quarter revenue increase of 43% year-over-year, reaching $30.8 million. This growth was primarily fueled by its pharmaceutical patient affordability segment, which saw revenue surge 110% to $16.6 million. The company is successfully transitioning from lower-margin legacy payment processing toward higher-margin software and assistance solutions. Despite the strong top-line performance, the company faces a temporary headwind in the fourth quarter due to the loss of 113 plasma collection centers to a banking partner, which is expected to reduce revenue by $1.5 million. However, management remains optimistic, citing robust software stickiness and a strong cash position of $34.5 million with zero bank debt to support long-term scaling into new medical verticals.

By The Motley Fool Team · Motley Fool ·

Paysign Reports 43% Revenue Growth Driven by Pharmaceutical Patient Affordability Segment

Topics: earnings report pharmaceutical services plasma collection centers revenue growth

Read the full article at Motley Fool

More World news